IDEAYA Biosciences, Inc. announced positive Phase 1 expansion data for IDE397 in methylthioadenosine phosphorylase (MTAP)-deletion urothelial cancer (UC) and non-small cell lung cancer (NSCLC) patients on October 25, 2024. The data was presented as a late breaker oral presentation at the 36th edition of the EORTC-NCI-AACR Symposium.
The clinical data from 27 evaluable patients at the 30 mg once-a-day Recommended Phase 2 Dose (RP2D) showed an overall response rate of approximately 33%, including one complete response and eight partial responses. A disease control rate of 93% was observed, with 25 of 27 evaluable patients achieving stable disease or better.
IDE397 demonstrated a favorable adverse event profile with no drug-related serious adverse events or discontinuations at the 30 mg QD expansion dose. Additionally, a preliminary clinical case study of the IDE397 and Trodelvy combination in MTAP-deletion UC showed a partial response and greater than 95% ctDNA reduction, supporting future combination development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.